Blog Layout

The Impact of HealthTech on Global Health Initiatives

July 28, 2024

The global healthcare landscape is undergoing a transformative evolution driven by rapid advancements in health technology (HealthTech). Innovations such as telemedicine, wearable devices, artificial intelligence (AI), and blockchain are revolutionizing how healthcare is delivered and managed, particularly in low- and middle-income countries (LMICs). These technologies are crucial for global health initiatives that aim to improve health outcomes and increase access to care worldwide. This blog explores the impact of HealthTech on global health initiatives and the investment opportunities they present.


Understanding HealthTech

HealthTech encompasses a broad array of technologies designed to enhance healthcare delivery and outcomes. Key components include:


Telemedicine: Telemedicine utilizes telecommunications technology to provide healthcare services remotely. It helps overcome geographical barriers and improves access to care, especially in remote and underserved areas. By enabling virtual consultations, telemedicine reduces the need for physical visits to healthcare facilities.


Wearable Devices: Wearable devices, such as fitness trackers and medical-grade sensors, monitor various health metrics in real-time. These devices collect data on heart rate, physical activity, sleep patterns, and more, providing valuable insights into an individual’s health and enabling proactive management of health conditions.


Artificial Intelligence and Machine Learning: AI and machine learning algorithms analyze vast amounts of healthcare data to support clinical decision-making, enhance diagnostics, and personalize treatment plans. These technologies can predict patient outcomes, identify disease patterns, and recommend appropriate interventions.


Big Data Analytics: Big data analytics involves processing and analyzing large datasets to uncover hidden patterns and insights. In healthcare, it can track disease outbreaks, monitor public health trends, and optimize resource allocation, thereby improving healthcare delivery and outcomes.


Blockchain: Blockchain technology ensures the secure and transparent sharing of health data. It enhances data privacy, streamlines administrative processes, and improves the traceability of medical supplies, reducing the risk of counterfeit drugs entering the supply chain.


Digital Health Platforms: Digital health platforms offer a range of services, including telemedicine, remote monitoring, mental health support, and personalized health interventions. These platforms provide convenient and accessible healthcare solutions to patients worldwide.


The Role of HealthTech in Global Health Initiatives

Global health initiatives focus on improving health outcomes, particularly in LMICs where healthcare challenges are most acute. HealthTech plays a crucial role in addressing key issues such as access to care, disease prevention and management, healthcare infrastructure, and health education.

Improving Access to Care


HealthTech significantly improves access to care by overcoming geographical barriers and addressing shortages of healthcare professionals. Telemedicine platforms enable remote consultations, diagnostics, and treatments, making healthcare accessible in underserved areas. For instance, platforms like Babylon Health and Ada Health provide AI-powered remote consultations and personalized health advice, extending healthcare services to remote populations.

Enhancing Disease Prevention and Management


Wearable devices and remote monitoring technologies enable continuous tracking of health metrics, allowing for early detection of health issues and timely interventions. This is particularly crucial for managing chronic diseases such as diabetes, hypertension, and cardiovascular diseases, which require ongoing monitoring and management.


AI and big data analytics play a vital role in tracking and predicting disease outbreaks. For instance, BlueDot, a Canadian health monitoring platform, uses AI to analyze vast amounts of data from various sources, including news reports, airline data, and public health databases, to predict and track the spread of infectious diseases. BlueDot successfully identified the COVID-19 outbreak days before it was officially recognized by health authorities.

Strengthening Healthcare Infrastructure


Building robust healthcare infrastructure is essential for improving health outcomes in LMICs. HealthTech can support this goal by streamlining administrative processes, enhancing supply chain management, and ensuring data integrity. Blockchain technology, for example, provides a secure and transparent way to manage health records, track medical supplies, and prevent counterfeit medications.


One notable example is the MediLedger Project, which uses blockchain to create an immutable ledger for tracking pharmaceuticals. This technology ensures the authenticity and traceability of medications, reducing the risk of counterfeit drugs entering the supply chain. Such innovations are critical for maintaining the integrity of healthcare systems and ensuring that patients receive safe and effective treatments.


Promoting Health Education and Awareness

Health education and awareness are fundamental components of global health initiatives. Digital health platforms and mobile apps provide accessible and engaging ways to educate individuals and communities about health and wellness. These platforms offer a range of resources, including educational videos, interactive quizzes, and personalized health tips, to empower individuals to take charge of their health.


For instance, the Safe Delivery App, developed by the Maternity Foundation, provides healthcare professionals with easy-to-access, evidence-based information on maternal and newborn health. The app includes instructional videos, checklists, and practical guidelines to support safe deliveries and improve maternal and neonatal outcomes. By enhancing the knowledge and skills of healthcare providers, such platforms contribute to better health outcomes for mothers and babies.


Case Studies of HealthTech Impact



To better understand the transformative potential of HealthTech in global health, it's helpful to examine specific case studies where these technologies have made a significant impact.


Case Study 1: Telemedicine in India

In India, telemedicine platforms have been pivotal in extending healthcare services to remote and rural areas. The eSanjeevani platform, developed by the Ministry of Health and Family Welfare, provides teleconsultation services to patients across the country. During the COVID-19 pandemic, eSanjeevani played a critical role in ensuring continued access to healthcare while minimizing the risk of virus transmission. The platform facilitated over one million teleconsultations, demonstrating the effectiveness of telemedicine in bridging the healthcare access gap.


Case Study 2: Wearable Devices in Chronic Disease Management

Wearable devices have revolutionized chronic disease management by enabling continuous monitoring and early detection of health issues. For example, Fitbit and Apple Watch have been widely used to track physical activity, heart rate, and sleep patterns. In clinical settings, wearable devices like the FreeStyle Libre, a continuous glucose monitor, have transformed diabetes management by providing real-time glucose readings and reducing the need for frequent finger-prick tests. These devices empower patients to take control of their health and facilitate timely interventions by healthcare providers.


Case Study 3: AI in Disease Prediction and Management

AI has been instrumental in predicting and managing disease outbreaks. During the Ebola outbreak in West Africa, AI-driven platforms like HealthMap and Metabiota analyzed data from various sources, including social media and news reports, to track the spread of the virus and predict future outbreaks. These platforms provided valuable insights that helped public health authorities implement targeted interventions and allocate resources effectively. The success of these AI-driven platforms highlights the potential of AI in enhancing disease surveillance and management.


Case Study 4: Blockchain in Supply Chain Management

Blockchain technology has been used to enhance the transparency and security of pharmaceutical supply chains. The MediLedger Project, for instance, leverages blockchain to track the movement of drugs from manufacturers to pharmacies. This technology ensures the authenticity of medications and prevents the distribution of counterfeit drugs. In addition to improving supply chain security, blockchain technology can streamline administrative processes and reduce costs by automating transactions and eliminating intermediaries.


The Impact of HealthTech on Global Health Initiatives


HealthTech innovations are fundamentally transforming global health initiatives, offering solutions to some of the most pressing healthcare challenges, particularly in low- and middle-income countries (LMICs). By leveraging advancements in telemedicine, wearable devices, artificial intelligence (AI), and blockchain, HealthTech enhances access to care, improves disease prevention and management, strengthens healthcare infrastructure, and promotes health education. These technologies not only bridge gaps in healthcare access and delivery but also empower individuals and communities to take control of their health.


The rapid growth of HealthTech presents numerous investment opportunities. Investors can capitalize on the increasing demand for digital health solutions and the expanding market for healthcare innovations. Key areas for investment include:


Telemedicine: The telemedicine market has experienced significant growth, driven by the need for remote healthcare services, especially during the COVID-19 pandemic. Investing in telemedicine platforms offers substantial growth potential as healthcare systems continue to integrate remote care.


Wearable Devices: The market for wearable devices is expanding rapidly, with increasing consumer interest in health and fitness tracking. These devices offer valuable applications in clinical settings for remote monitoring and chronic disease management. Investing in companies that develop innovative wearable technologies can yield significant returns.


AI and Machine Learning: AI and machine learning are transforming healthcare by enabling more accurate diagnostics, personalized treatments, and efficient resource management. Startups and established companies focusing on AI-driven healthcare solutions present attractive investment opportunities. Investors should look for companies with strong technical expertise, robust data management practices, and a clear path to regulatory compliance.


Digital Health Platforms: Digital health platforms that offer comprehensive health services, including telemedicine, mental health support, and remote monitoring, are gaining traction. These platforms provide scalable and cost-effective solutions to meet the growing demand for healthcare services. Investing in digital health platforms with a proven track record and a strong user base can provide stable returns and growth potential.


Blockchain Technology: Blockchain technology offers unique solutions to enhance data security, supply chain management, and administrative efficiency in healthcare. Companies that leverage blockchain for health data management, pharmaceutical tracking, and secure transactions present promising investment opportunities. Investors should focus on companies with innovative blockchain applications and strategic partnerships with healthcare organizations.


Future Trends in HealthTech


The future of HealthTech is shaped by ongoing advancements in technology and the evolving needs of healthcare systems. Emerging trends in HealthTech include personalized medicine, precision health, genomics, and integrated care models. These trends hold the potential to further revolutionize healthcare delivery and outcomes.


Personalized Medicine and Precision Health: Personalized medicine involves tailoring medical treatments and interventions to an individual’s unique genetic makeup, lifestyle, and health history. Advances in genomics and AI are driving the development of personalized therapies that target specific genetic mutations and molecular pathways. This approach promises to improve treatment efficacy and reduce adverse effects.


Genomics: Genomics is the study of an individual’s genetic material and its impact on health and disease. Advances in genomic sequencing technologies have made it possible to decode the entire human genome at a relatively low cost. This has opened up new possibilities for understanding the genetic basis of diseases and developing targeted therapies. Companies like Illumina and 23andMe are leading the way in genomics, offering genetic testing services that provide insights into an individual’s genetic predisposition to various health conditions.


Integrated Care Models: Integrated care models aim to provide seamless and coordinated healthcare services across different settings and providers. HealthTech plays a crucial role in facilitating integrated care by enabling data sharing, communication, and collaboration among healthcare professionals. Digital health platforms and electronic health records (EHRs) are essential components of integrated care models. For example, the CareConnect platform developed by the Mayo Clinic integrates patient data from various sources, including EHRs, wearable devices, and telemedicine services, to provide a comprehensive view of a patient’s health. This integrated approach enhances care coordination, improves patient outcomes, and reduces healthcare costs.


Challenges and Considerations for HealthTech Investments


While HealthTech presents significant investment opportunities, there are also challenges and considerations that investors must navigate. These include regulatory compliance, data privacy, technological feasibility, market adoption, and the competitive landscape.


Regulatory Compliance: HealthTech innovations must comply with various regulatory standards to ensure safety and efficacy. Navigating the regulatory landscape can be complex, as different countries have different requirements. Investors should focus on companies with a clear regulatory strategy and a track record of successful regulatory approvals.


Data Privacy and Security: Handling sensitive health data requires robust privacy and security measures. Data breaches and non-compliance with data protection regulations can lead to significant legal and financial repercussions. Companies must implement stringent data security protocols and comply with regulations such as the General Data Protection Regulation (GDPR) and the Health Insurance Portability and Accountability Act (HIPAA).


Technological Feasibility: The success of HealthTech innovations depends on their technological feasibility and scalability. Investors should assess the technical capabilities of companies and their ability to integrate new technologies into existing healthcare systems. Innovations that demonstrate scalability and interoperability are more likely to achieve widespread adoption.


Market Adoption: Market adoption is a critical factor for the success of HealthTech innovations. Investors should evaluate the market demand for the technology and the company’s go-to-market strategy. Companies that have established partnerships with healthcare providers and demonstrate strong user engagement are well-positioned for market adoption.


Competitive Landscape: The HealthTech sector is highly competitive, with numerous startups and established companies vying for market share. Investors should conduct thorough competitive analysis to identify companies with unique value propositions, strong intellectual property, and competitive advantages.


Conclusion


HealthTech is revolutionizing global healthcare by improving access to care, enhancing disease prevention and management, strengthening healthcare infrastructure, and promoting health education. These innovations are crucial for global health initiatives, particularly in LMICs where healthcare challenges are most acute. The rapid growth of HealthTech presents numerous investment opportunities, particularly in areas such as telemedicine, wearable devices, AI and machine learning, digital health platforms, and blockchain technology.


While investing in HealthTech offers significant potential for returns, investors must navigate challenges such as regulatory compliance, data privacy, technological feasibility, market adoption, and competitive landscape. By carefully evaluating these factors, investors can identify promising opportunities and contribute to the advancement of global health.


The future of HealthTech is bright, with emerging trends such as personalized medicine, precision health, genomics, and integrated care models set to further revolutionize healthcare delivery and outcomes. By supporting these innovations, investors can play a pivotal role in transforming healthcare and improving health outcomes worldwide.


In conclusion, HealthTech is a powerful catalyst for global health initiatives, offering solutions to some of the most pressing healthcare challenges. The integration of advanced technologies into healthcare systems is not only improving patient outcomes but also creating more sustainable and efficient healthcare delivery models. Investing in HealthTech is not only a sound financial decision but also a way to make a meaningful impact on global health.

A nurse is holding a bottle of pills in her hand.

HealthTech Innovations in Chronic Disease Management

July 29, 2024
Discover how HealthTech innovations are transforming chronic disease management. This blog highlights the latest technologies like remote monitoring, AI, and mobile apps, which improve patient care, outcomes, and reduce costs. Explore real-world examples and see how personalized and preventive approaches enhance quality of life for millions.
A female doctor wearing a white coat with a stethoscope around her neck.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

By Daniel Ferry • July 29, 2024
Notable Labs is a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of “Clearance to Proceed” from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming months.
A man in a lab coat and mask is holding a box of test tubes.

Notable Labs: Revolutionizing Pediatric Leukemia Treatment

By Syeda Abeer Iqbal • July 29, 2024
Notable Labs is transforming pediatric leukemia treatment with its Predictive Precision Medicines Platform (PPMP), which boasts a 97% predictive precision. This platform rapidly identifies the most effective treatments for individual patients, significantly reducing the time and cost of cancer therapy. Notable Labs focuses on personalized medicine, combining high-throughput screening and machine learning to predict patient responses and tailor treatments accordingly. Their innovative approach has shown promising results in clinical validation studies, offering new hope for improving outcomes in pediatric leukemia.
A man in a lab coat is pushing a cart down a hallway.

Notable Labs' Innovative Approach to Cancer Treatment

By Scott Smith • July 29, 2024
Notable Labs is revolutionizing cancer treatment with its innovative approach to combination therapy, which targets multiple cancer pathways simultaneously. Their Predictive Precision Medicine Platform (PPMP) leverages advanced data analysis and machine learning to identify the most effective drug combinations for individual patients. By using high-throughput screening and bio-simulation, Notable Labs accelerates drug development, reduces costs, and improves clinical trial success rates. This approach promises significant improvements in patient outcomes, particularly for pediatric leukemia, by providing personalized, effective treatments and minimizing side effects.
A woman is laying in a dental chair in a dark room looking up.

Notable Labs Revolutionizing Precision Medicine

By Ayushi Hisaria • July 29, 2024
Notable Labs' cutting-edge diagnostic technology, boasting a 95% prediction accuracy per a Stanford study, is set to revolutionize pediatric leukemia treatment by identifying the most effective therapies. Their mission centers on advancing precision diagnostics to enhance therapy efficacy for young patients. Utilizing high-throughput screening and machine learning, Notable's platform offers tailored treatment plans, significantly improving outcomes for rare and aggressive forms of leukemia. This approach holds promise for personalized medicine, ensuring each child receives optimal, life-saving care.
A woman wearing headphones and a red sweater is stretching her arms in the woods.

How Notable Labs is Revolutionizing Cancer Treatment

By Kathleen Mackay • July 29, 2024
Notable Labs is transforming cancer treatment with its innovative combination therapy approach. By leveraging its Predictive Precision Medicine Platform (PPMP), Notable identifies optimal drug combinations tailored to individual patients. This methodology aims to reduce the development of resistant cancer cells and allows each drug to be used at its best dosage without intolerable side effects. The platform has shown impressive predictive accuracy in clinical trials, particularly for pediatric leukemia. Notable's commitment to precision medicine offers new hope for patients with high unmet medical needs, driving better treatment outcomes and enhancing quality of life.
Two little girls are sitting at a table painting with brushes.

Innovative Diagnostics for Pediatric Leukemia: The Notable Labs Advantage

By Fabian Goguta • July 29, 2024
Notable Labs leverages predictive precision medicine to revolutionize cancer treatment, particularly pediatric leukemia. Their Predictive Medicine Platform (PMP) uses advanced technologies like flow cytometry and machine learning to analyze patient-specific cancer cell responses, offering highly accurate predictions for effective treatments. Clinical validation studies have shown a 97% precision in predicting responders. Collaborations with renowned institutions like Texas Children’s Hospital and UCSF further highlight Notable's commitment to improving pediatric oncology outcomes, making personalized, rapid, and effective cancer treatments a reality.
A woman and a little girl are sitting on the floor.

Precision Medicine in Pediatric Leukemia

By Divya Narasimhan, MSc • July 29, 2024
Precision medicine is revolutionizing pediatric leukemia treatment by offering tailored therapies based on individual genetic profiles. Notable Labs’ predictive precision medicine platform, driven by machine learning, is at the forefront of this transformation. With a 95% accuracy rate, this technology identifies the most effective treatments for rare and aggressive leukemia subtypes, such as pAML and JMML, ensuring better outcomes. This blog explores the advanced technological foundations, life-saving impact, and promising future of Notable Labs' approach in personalized cancer care for children.
A person is holding a baby 's hand on a bed.

Precision Medicine in Childhood Leukemia

By Dr. David Letsa • July 29, 2024
Notable Labs, founded by Matthew De Silva, emerged from his personal quest to find better treatments for glioblastoma after his father's diagnosis. Partnering with Dr. Thomas Bock, De Silva's vision turned into a biotech startup revolutionizing cancer treatment through its Predictive Precision Medicine Platform (PPMP). The company's leadership team includes industry veterans like Dr. Joseph Wagner, Dr. Glenn Michelson, and Scott McPherson. Headquartered in Foster City, California, Notable Labs collaborates with top hospitals and leverages cutting-edge drug screening technology to deliver personalized cancer therapies, significantly improving patient outcomes.
A microscope is sitting on top of a table in a laboratory.

The Promise of Combination Therapy

By Dr. Anjaney Kothari • July 29, 2024
Given the complexity of the biological mechanisms that underlie cancer, it is prudent to identify and target more than one Achilles’ heel to attack this multifactorial disease. This can be achieved by employing combination therapy, an approach to cancer treatment that combines multiple therapeutic agents to improve patient outcomes. Notable Labs is at the forefront of revolutionary advancements in combination therapy, one noteworthy example being its long-standing collaboration with Syros Pharmaceuticals. For Syros, Notable developed a highly efficient predictive biological test to screen patients for the clinical trial of a combination therapy against non-acute promyelocytic leukemia (APL) acute myeloid leukemia (AML). Notable Labs’ innovative approach to combination therapy holds immense promise for significantly improving cancer treatment outcomes despite current limitations in commercial pursuit. This blog dives into the science behind the promise of combination therapy, how Notable is contributing toward the evolution of this technology, and why the company’s Board of Directors is excellently positioned to advance this field in the future. Notable Labs' investigation into combination therapy against cancer is backed by decades of scientific research. Combination therapy holds immense promise in the fight against cancer because of its ability to additively or synergistically target two or more cancer pathways. Due to its multi-target approach, combination therapy is also an effective strategy to overcome anti-cancer drug resistance. By collaborating with Syros in 2017, Notable Labs contributed to the phase II clinical trial of a therapy combining the drugs tamibarotene and azacitidine against non-APL AML. For this multi-arm monotherapy and combination therapy trial, Notable developed a blood-based biomarker test to help predict patient response to treatment. Specifically, Notable was involved in conducting ex vivo experiments on peripheral blood mononuclear cells (PBMCs) isolated from the blood samples of non-APL AML patients. Harnessing the power of high-throughput flow cytometry, these experiments revealed that a 72-hour ex vivo exposure of PBMCs to tamibarotene upregulates various markers of myeloid cell differentiation, including the RARα pathway target CD38. Importantly, treatments that can promote myeloid cell differentiation are known to be effective against some subtypes of AML. Therefore, by testing a patient’s blood sample using Notable’s ex vivo approach, it is possible to predict whether the patient is likely to respond well to tamibarotene in monotherapy and combination therapy. Indeed, Notable’s ex vivo assay became one of the strategies Syros adopted when screening patients for enrolment in the phase II clinical trial of tamibarotene (alone as well as in combination with azacitidine). Market Challenges Currently, cancer treatment – and thus, the oncology market as a whole – is faced with a three-pronged challenge. There are millions of non-responders who are not benefiting from chemotherapeutic drugs, thousands of compelling drugs that need to be shelved because of perceived non-response, and hundreds of promising candidate drugs that are struggling to navigate the drug development pipeline. Notable Labs is committed to resolving these challenges through its successfully tested predictive precision medicine pipeline, a significant application of which was demonstrated during the Syros clinical trial.  Notable Labs’ commitment is also one of the reasons why it has decided not to commercialize the combination therapy technology immediately. Notable wants to focus on refining the technology further, expanding its applications, and ensuring that it integrates seamlessly into existing healthcare systems. The company aims to develop more sophisticated prediction models and address regulatory and logistical challenges. This approach will help make Notable's technology accessible to a broader patient population, maximizing the life-saving potential of predictive diagnostics as well as combination therapy. Broader Applications The high-throughput nature of Notable’s ex vivo flow-cytometry-based predictive precision medicine pipeline has helped identify many powerful drug combinations to treat other cancers such as juvenile myelomonocytic leukemia. This pipeline also has great potential for identifying effective drug combinations and guiding patient enrolment in clinical trials of combination therapies for other cancers, including solid tumors. In the case of solid tumors, the Notable pipeline’s blood samples for ex vivo testing could be replaced by biopsy samples, circulating tumor cells, pleural effusion, or ascites, among other sampling options. Founding Story Notable’s CEO, Dr. Thomas Bock (MD, MBA), has ensured that the company is well-positioned to transform combination therapy for cancer. For decades, our CEO has worked on multiple dimensions of oncology, including precision medicine, prevention of inherited cancers, and cancer vaccines. At Notable, Dr. Bock combines his medical and business training to accomplish the company’s mission of dramatically improving patient outcomes and the success, speed, and cost of developing new medicines. Strength of the Board of Directors Notable’s esteemed Board of Directors boasts of more than 150 years of combined professional experience in premier life science companies. Our board members excel in medicine (Dr. Bock), pharmacology (Mr. Tuomo Pätsi), business (Dr. Bock), finance (Mr. Michael Rice, Mr. Peter Feinberg, Mr. Thomas Graney), media communications (Ms. Michele Galen), and law (Mr. Thomas Dubin), fostering a vibrant and eclectic environment for Notable to thrive. This diverse team of bona fide giants from the pharmaceutical and biotechnology sectors is set to efficiently guide Notable Labs on its path to success in combination therapy and beyond. Conclusion Combination therapy for cancer, aided by predictive methods, could significantly improve patient outcomes while also broadening the population of patients who can benefit from a given drug combination. Leading the charge in this direction, Notable Labs’ predictive precision medicine pipeline boasts of massive potential to not only identify effective drug combinations for combination therapy, but also guide patient enrolment in clinical trials through predictive screening. Moving ahead, Notable’s technology is set to transform the treatment of multiple types of cancer by ensuring positive patient outcomes of personalized combination therapies in shorter times and at lower costs. Additional Data Points AML statistics (American Cancer Society): estimated 20,800 new diagnoses and 11, 220 deaths in the US in 2024. Success stories and collaborations in the field of combination therapy: Notable’s collaboration with Syros to develop a predictive test for patient response to monotherapy and combination therapy. Potential impact on cancer treatment outcomes: Combination therapy, aided by predictive methods, has the potential to enhance patient outcome while also broadening the population of patients who can benefit from a given combination of drugs. Future directions for research and development: AML treatment strategies must pivot towards personalized/precision medicine because of overwhelming heterogeneity of the disease. References Combination therapy in combating cancer . (2017). Oncotarget Notable’s collaboration with Syros . (2017). Notable Labs + Syros Differentiation therapy for myeloid malignancies: beyond cytotoxicity . (2021). Blood Cancer Journal New strategies to treat AML: novel insights into AML survival pathways and combination therapies . (2021). Leukemia Precision oncology using ex vivo technology: a step towards individualised cancer care? . (2022). Expert Reviews in Molecular Medicine Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML . (2023). Blood Advances Notable Labs’ JMML data . (2023). Notable Labs Key statistics for acute myeloid leukemia (AML) . (2024). American Cancer Society About the Author Dr. Anjaney Kothari is a scientific writer and researcher with a decade of experience in biomedical research. He completed his Ph.D. in Biomedical Engineering from Virginia Tech (USA) in 2019, developing and characterizing holistic in vitro and ex vivo models of hepatic and gastrointestinal toxicity. He has since been working as a freelance writer and researcher for companies operating in diverse niches, including biotechnology and biopharmaceuticals. Disclaimer The content of these blogs reflects the research and opinions of the individual authors and does not necessarily represent the views or positions of Notable Labs or its affiliates. The information provided is for educational and informational purposes only and should not be construed as medical, legal, or financial advice. Notable Labs makes no representations as to the accuracy, completeness, or validity of any information in these blogs and will not be liable for any errors, omissions, or any losses, injuries, or damages arising from their use. These blogs may reference third-party research, studies, or resources. Notable Labs does not endorse or assume responsibility for the content or practices of these third parties. Any reliance on the information provided is at the reader's own risk. For biotechnology and pharmaceutical content, note that ongoing research and clinical trials may change the context and results discussed. Always refer to the latest research and guidelines from reputable sources.
More Posts
Share by: